AC
RANI icon

Armistice Capital’s Rani Therapeutics RANI Stock Holding History

Armistice Capital’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,151,354
Closed -$1.62M – 378
2025
Q2 		$1.62M Buy
+3,151,354
New +$2.57M 0.03% 139
2024
Q4 		– Sell
-2,574,000
Closed -$5.56M – 291
2024
Q3 		$5.56M Buy
+2,574,000
New +$7.38M 0.09% 117

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Armistice Capital's RANI Position: Q3 2025 in Review

Armistice Capital sold out of Rani Therapeutics (RANI) in Q3 2025, closing a stake of 3,151,354 shares — an estimated $1.62M sold.

Armistice Capital first reported a position in RANI in Q3 2024 and held it in 2 quarters. The position peaked at $5.56M in Q3 2024. 38 funds tracked by Wall St. Rank hold RANI as of Q3 2025.

  • Armistice Capital reported no remaining Rani Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 3,151,354 Rani Therapeutics shares in Q3 2025, an estimated $1.62M.
  • Armistice Capital first reported a position in Rani Therapeutics in Q3 2024 and held it in 2 quarters.
  • Armistice Capital's Rani Therapeutics position peaked at $5.56M in Q3 2024.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.